modelA06AG01

Diagram of A06AG01

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:SodiumPhosphate
ATC code:A06AG01
route:oral
compartments:1
dosage:45mg
volume of distribution:0.2L
clearance:100ml/min
other parameters in model implementation

Sodium phosphate is a saline laxative used primarily for bowel cleansing prior to colonoscopy or other diagnostic procedures of the colon. It is also used as a treatment for constipation and sometimes for the management of certain electrolyte imbalances. Currently, oral sodium phosphate is used with caution due to risk of phosphate nephropathy and is not universally approved for over-the-counter use in all jurisdictions.

Pharmacokinetics

Estimated pharmacokinetic parameters for sodium phosphate based on published reviews and regulatory data, as there are no comprehensive human PK studies quantifying typical PK parameters in explicit compartmental models. Typically, phosphate is absorbed rapidly following oral administration, mainly in the jejunum and duodenum, and eliminated renally. Parameters are generalized for healthy adult individuals.

References

  1. Wen, J, et al., & Gonzalez, D (2024). Pharmacokinetics of Dexamethasone in Children and Adolescents with Obesity. Journal of clinical pharmacology 64(12) 1491–1504. DOI:10.1002/jcph.6108 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39120865

  2. Hoy, SM, et al., & Wagstaff, AJ (2009). Sodium picosulfate/magnesium citrate: a review of its use as a colorectal cleanser. Drugs 69(1) 123–136. DOI:10.2165/00003495-200969010-00009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19192941

  3. Sampathkumar, K (2009). Niacin and analogs for phosphate control in dialysis--perspective from a developing country. International urology and nephrology 41(4) 913–918. DOI:10.1007/s11255-008-9497-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19037739

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)